drugset / Trial / NCT05190315

Chlorpromazine and Standard of Care in Glioblastoma

NCT05190315

Phase 1 Completed 10 enrolled Mohammed Milhem
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 study investigating the re-purposing of chlorpromazine, combined with temozolomide and radiation in the treatment of newly diagnosed glioblastoma multiforme.

Timeline

Start
2022-01-28
Primary completion
2023-04-25
Completion
2024-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorpromazine Small molecule 25 mg Oral
Subject Chlorpromazine Small molecule 50 mg Oral
Background Temozolomide Small molecule 200 mg/m2 Oral

Indications